Search results for
5187 items
Equality and Human Rights Consultation - NICE TA - Dabrafenib in Combination with Trametinib for Adjuvant Treatment of Resected BRAF V600 Positive Malignant Melanoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cabozantinib for Untreated Advanced Renal Cell Carcinoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Inotuzumab Ozogamicin for Treating Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Dinutuximab Beta for Treating High-Risk Neuroblastoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Lutetium (177lu) Oxodotreotide for Treating Unresectable or Metastatic Neuroendocrine Tumours
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Alectinib for Untreated Anaplastic Lymphoma Kinase Positive Advanced Non-Small-Cell Lung Cancer
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ixekizumab for Treating Active Psoriatic Arthritis After DMARDs
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ocrelizumab for Treating Relapsing Multiple Sclerosis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Dupilumab for Treating Moderate to Severe Atopic Dermatitis after Topical Treatments
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cenegermin for Treating Neurotrophic Keratitis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pembrolizumab for Untreated PD-L1 Positive Metastatic Non-Small-Cell Lung Cancer (CDF Review of TA447)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Beta Interferon and Glatiramer Acetate for Treating Multiple Sclerosis (Review of TA32)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Atezolizumab for Treating Metastatic Urothelial Cancer after Platinum-Based Chemotherapy
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Midostaurin for Untreated Acute Myeloid Leukaemia
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Brentuximab Vedotin for Treating CD30-Positive Hodgkin Lymphoma (Review of TA446)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Guselkumab for Treating Moderate to Severe Plaque Psoriasis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Atezolizumab for Treating Non-Small-Cell Lung Cancer after Platinum-Based Chemotherapy
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the